SCHEMBL2016108

SCHEMBL2016108

CC1(C)CCC(C)(C)c2cc(-c3nccc(N4CCC(NCC(O)CO)CC4)n3)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 2/20 0.41
CDK4 P11802 2/20 0.36
CDK6 Q00534 2/20 0.36
RARB P10826 2/20 0.36
RARG P13631 1/20 0.36
CYP3A4 P08684 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
PIK3CD O00329 2/20 0.34
PIK3CA P42336 2/20 0.34
HRH4 Q9H3N8 3/20 0.34
RORC P51449 2/20 0.34
PRMT5 O14744 1/20 0.34
ACACB O00763 1/20 0.34
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2016107 1.00 PTPN11 (0.41) PTPN11CDK4CDK6RARBRARG
SCHEMBL2012956 1.00 PTPN11 (0.41) PTPN11CDK4CDK6RARBRARG
SCHEMBL2013178 0.95 HRH4 (0.39) PTPN11RARBRARGHRH4ACACB
SCHEMBL2015668 0.95 HRH4 (0.39) PTPN11RARBRARGHRH4ACACB
SCHEMBL2013182 0.95 HRH4 (0.39) PTPN11RARBRARGHRH4ACACB
SCHEMBL2018417 0.85 PTPN11 (0.46) PTPN11CDK4CDK6RARBCYP3A4
SCHEMBL12959458 0.85 PTPN11 (0.46) PTPN11CDK4CDK6RARBCYP3A4
SCHEMBL2017787 0.85 RARB (0.44) CDK4CDK6RARBRARGCYP3A4
SCHEMBL2014325 0.85 DKK1 (0.42) PTPN11CDK4CDK6RARBRARG
SCHEMBL2014322 0.85 DKK1 (0.42) PTPN11CDK4CDK6RARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
EP-2513057-A1 SPHINGOSINE KINASE INHIBITORS Merck Patent GmbH (DE) 2012-10-24 EP disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, SPHK2, S1PR3 PTPN11 1089/4885CDK4 1382/4885CDK6 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.